Context Therapeutics Inc (CNTX) - Net Assets
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has net assets worth $52.20 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($58.86 Million) and total liabilities ($6.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Context Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.20 Million |
| % of Total Assets | 88.69% |
| Annual Growth Rate | 18.51% |
| 5-Year Change | 25.28% |
| 10-Year Change | N/A |
| Growth Volatility | 300.07 |
Context Therapeutics Inc - Net Assets Trend (2016–2025)
This chart illustrates how Context Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore Context Therapeutics Inc (CNTX) cash flow conversion to assess how effectively this company generates cash.
Annual Net Assets for Context Therapeutics Inc (2016–2025)
The table below shows the annual net assets of Context Therapeutics Inc from 2016 to 2025. For live valuation and market cap data, see Context Therapeutics Inc (CNTX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $60.47 Million | -36.52% |
| 2024-12-31 | $95.27 Million | +702.51% |
| 2023-12-31 | $11.87 Million | -65.85% |
| 2022-12-31 | $34.76 Million | -28.00% |
| 2021-12-31 | $48.27 Million | +385.28% |
| 2020-12-31 | $-16.92 Million | +29.38% |
| 2019-12-31 | $-23.96 Million | -140.64% |
| 2017-12-31 | $58.95 Million | +349.50% |
| 2016-12-31 | $13.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Context Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5809830900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.88K | 0.15% |
| Other Components | $191.29 Million | 316.31% |
| Total Equity | $60.47 Million | 100.00% |
Context Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Context Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thantawan Industry Public Company Limited
BK:THIP
|
$58.07 Million |
|
CTI Traffic Industries Co Ltd
TWO:2230
|
$58.08 Million |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
$58.09 Million |
|
Globaltec Formation Bhd
KLSE:5220
|
$58.11 Million |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
$58.05 Million |
|
Pengana Capital Group Ltd
AU:PCG
|
$58.05 Million |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
$58.05 Million |
|
Duroc AB (publ)
ST:DURC-B
|
$58.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Context Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 95,266,262 to 60,473,727, a change of -34,792,535 (-36.5%).
- Net loss of 36,123,615 reduced equity.
- Other factors increased equity by 1,331,080.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.12 Million | -59.73% |
| Other Changes | $1.33 Million | +2.2% |
| Total Change | $- | -36.52% |
Book Value vs Market Value Analysis
This analysis compares Context Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.19 | $0.63 | x |
| 2020-12-31 | $-1.54 | $0.63 | x |
| 2021-12-31 | $17.03 | $0.63 | x |
| 2022-12-31 | $2.18 | $0.63 | x |
| 2023-12-31 | $0.74 | $0.63 | x |
| 2024-12-31 | $1.63 | $0.63 | x |
| 2025-12-31 | $0.64 | $0.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Context Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-59.73%) is above the historical average (-75.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -287.24% | 0.00% | 0.00x | 1.83x | $-38.98 Million |
| 2017 | -41.75% | 0.00% | 0.00x | 1.16x | $-30.51 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.09 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $8.34 Million |
| 2021 | -21.66% | 0.00% | 0.00x | 1.06x | $-15.28 Million |
| 2022 | -42.68% | 0.00% | 0.00x | 1.09x | $-18.31 Million |
| 2023 | -201.87% | 0.00% | 0.00x | 1.35x | $-25.15 Million |
| 2024 | -28.05% | 0.00% | 0.00x | 1.03x | $-36.25 Million |
| 2025 | -59.73% | 0.00% | 0.00x | 1.13x | $-42.17 Million |
Industry Comparison
This section compares Context Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Context Therapeutics Inc (CNTX) | $52.20 Million | -287.24% | 0.13x | $58.06 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the de… Read more